Biophytis S.A. files H1 2025 interim report

Biophytis S.A., a foreign private issuer based in Paris, submitted a Form 6-K to provide investors with its Interim Financial Report for the first half of fiscal year 2025.

Rhea-AI Filing Summary

Biophytis S.A., a foreign private issuer based in Paris, submitted a Form 6-K to provide investors with its Interim Financial Report for the first half of fiscal year 2025. The company states that this interim report, dated October 31, 2025, is attached as Exhibit 99.1 and incorporated by reference, meaning the detailed financial and operational information for the period is contained in that exhibit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Biophytis S.A. (BPTSY) file in this Form 6-K?

Biophytis S.A. filed a Form 6-K to furnish its Interim Financial Report for the first half of fiscal year 2025, attached as Exhibit 99.1.

Which financial period does Biophytis S.A.’s interim report on this 6-K cover?

The interim report furnished with this Form 6-K covers the first half of fiscal year 2025 for Biophytis S.A.

Where can investors find the detailed 2025 interim financial information for Biophytis S.A. (BPTSY)?

The detailed interim financial information is included in the Interim Financial Report attached as Exhibit 99.1 to this Form 6-K.

What type of SEC filer is Biophytis S.A. in this document?

Biophytis S.A. identifies itself as a foreign private issuer and indicates that it files annual reports under cover of Form 20-F.

Who signed the Biophytis S.A. Form 6-K for the 2025 interim report?

The Form 6-K was signed on behalf of Biophytis S.A. by Stanislas Veillet, its Chairman and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 09:22 AM EDT Learn about SEC filing dates

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: October 31, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On October 31, 2025, Biophytis S.A. issued its Interim Financial Report for the first half of fiscal year 2025. A copy of the Company’s Interim Financial Report is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

EXHIBIT LIST

Exhibit		Description
99.1		Interim Financial Report by the registrant on October 31, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.
Date: October 31, 2025	By:
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer